| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2006;37:235.)
© 2006 American Heart Association, Inc.
Research Reports |
From the Experimental Cardiology Laboratory (J.P.G.S., W.P.C.P., A.H.S., E.V., C.F.S., D.P.V.d.K., G.P.) and Vascular Surgery (F.M.), University Medical Center, Utrecht; Interuniversity Cardiology Institute of the Netherlands (J.P.G.S., A.H.S., D.P.V.d.K.), Utrecht; Vascular Surgery (J.P.d.V.), Nieuwegein; and Biomedical Research (J.V., R.H.), The Netherlands Organization for Applied Scientific Research (TNO), Leiden, the Netherlands.
Correspondence to Gerard Pasterkamp, MD, PhD, University Medical Center, Experimental Cardiology Laboratory, Heidelberglaan 100, Room G02-523, 3584 CX Utrecht, the Netherlands. E-mail g.pasterkamp{at}hli.azu.nl
| Abstract |
|---|
|
|
|---|
Methods Carotid atherosclerotic plaques (n=150) were stained and analyzed for the presence of collagen, smooth muscle cell (SMC), and macrophages. Adjacent segments were used to isolate total protein to assess MMP-2 and MMP-9 activities and gelatin breakdown, MMP-8 activity, and EMMPRIN levels.
Results Macrophage-rich lesions revealed higher MMP-8 and MMP-9 activities, whereas SMC-rich lesions showed higher MMP-2 activity. The levels of less glycosylated EMMPRIN-45kD were higher in SMC-rich lesions and lower in macrophage-rich plaques. EMMPRIN-45kD was associated with MMP-2 levels, whereas EMMPRIN-58kD was related to MMP-9 levels.
Conclusions MMP-2, MMP-8, and MMP-9 activities differed among carotid plaque phenotypes. Different EMMPRIN glycosylation forms are associated with either MMP-2 or MMP-9 activity, which suggests that EMMPRIN glycosylation may play a role in MMP regulation and plaque destabilization.
Key Words: atherosclerosis carotid arteries carotid artery plaque endarterectomy inflammation matrix metalloproteinases
| Introduction |
|---|
|
|
|---|
Extracellular MMP inducer (EMMPRIN) stimulates the production of different MMPs.4 EMMPRIN has been identified in human macrophagerich atheroma.5 However, the relation of EMMPRIN with plaque characteristics and MMP expression remains to be elucidated. In the present study, carotid endarterectomy plaque characteristics were associated with MMP-2, MMP-8, and MMP-9 activities and EMMPRIN expression levels.
| Methods |
|---|
|
|
|---|
The adjacent segment was used to isolate total protein and MMP-2, MMP-8, and MMP-9. Total MMP activities were measured using the Biotrak activity assays RPN2631, RPN2635, and RPN2634, respectively (Amersham Biosciences). To determine pro- and active MMP-2 and MMP-9 levels in each plaque, zymography was performed as described elsewhere.7 EMMPRIN expression levels were determined by Western blotting (sc-9753, Santa Cruz Biotechnology).
Human SMCs (CRL-1999, American Type Culture Collection) and monocytes (THP-1 and TIB-202, American Type Culture Collection) were cultured according to the manufacturer. Total cell protein was isolated by using Tripure Isolation Reagent (Boehringer Mannheim), and EMMPRIN expression and MMP activity were studied.
Data are presented as mean and 95% CI. One-way ANOVA, MannWhitney test, or KruskalWallis test was used to compare differences among histological sections and EMMPRIN with MMP levels. P values of <0.05 were considered significant.
| Results |
|---|
|
|
|---|
-actin, and less collagen staining (Figure 1). MMP-8 activity levels were increased in plaques that revealed more CD68 staining. In contrast, MMP-2 activity levels were increased in fibrous plaques and in plaques with more SMC staining. Regression analysis among MMP-2, MMP-8, and MMP-9 levels showed a relation between MMP-8 and MMP-9 (r=0.59, B=1.38, P<0.001).
|
Higher EMMPRIN-45kD levels were observed in sections heavily stained for SMC, but lower EMMPRIN-45kD expression levels were found in macrophages-rich sections. No differences in EMMPRIN-58kD levels were observed between groups.
EMMPRIN has been reported to induce MMP expression and not MMP activation directly. Therefore, we studied the relation between EMMPRIN levels not only with MMP activity levels but also with the amount of gelatin breakdown of the individual active and inactive MMP-2 and MMP-9 levels obtained by zymography. Regression analysis between both MMP methods revealed a consistent expression pattern and comparable plaque results (data not shown).
A significant relation was observed between EMMPRIN-45kD and MMP-2, and an inverse relation was observed with MMP-8 and 9 activity levels (Figure 2). Also, a significant correlation between EMMPRIN-45kD and gelatin breakdown by pro-MMP-2 levels was detected. EMMPRIN-58kD was inversely associated with gelatin breakdown by pro-MMP-2 and with active MMP-9, as determined by zymography (Figure 2).
|
Immunoreactivity to EMMPRIN in the atherosclerotic lesions was observed in both macrophage-rich and SMC-rich areas (Figure 3 A and 3B). This was confirmed on cell lysates of cultured SMCs and macrophages (Figure 3C). Interestingly, macrophages contained relatively more EMMPRIN-58kD and MMP-9, whereas SMCs produced more EMMPRIN-45kD and MMP-2 (Figure 3D), confirming the observations in atherosclerotic plaques.
|
| Discussion |
|---|
|
|
|---|
We observed previously a more diffuse staining throughout the atherosclerotic plaque for MMP-2 not specifically colocalized with macrophages and that both MMP-2 and MMP-9 immunoreactivity were more prevalent in expansively remodeled plaques,7 associated with unstable angina.10 However, in the present study, a large number of specimens was studied showing a clear differentiation in MMP-2 expression among plaque phenotypes. Increased MMP-2 activity levels were associated with SMC presence and a fibrous phenotype, suggesting that MMP-2 expression is associated with a stable lesion phenotype.
Different forms of EMMPRIN can be produced by different modes of glycosylation,11 but it remains to be elucidated how glycosylation can regulate its induction capacity. In the present study, EMMPRIN-45kD expression levels correlated with the presence of SMC, whereas EMMPRIN-58kD was expressed by both macrophages and SMCs but more abundantly by macrophages. Furthermore, both EMMPRIN forms were associated with different MMP expression patterns. This suggests that different cell types produce different amounts of EMMPRIN-45kD and -58kD, resulting in a different MMP repertoire. Preliminary analysis revealed a trend to decreased EMMPRIN-45kD and increased EMMPRIN-58kD levels in patients with clinical symptoms (data not shown).
In conclusion, MMP-8 and MMP-9 activity levels are increased in more unstable plaques, whereas MMP-2 activity levels are higher in stable lesions. MMP expressions were associated with differently glycosylated EMMPRIN forms. Differences in EMMPRIN forms are also observed among plaque phenotypes; therefore, EMMPRIN may play a role in MMP regulation and plaque destabilization.
| Acknowledgments |
|---|
Received August 17, 2005; revision received October 6, 2005; accepted October 21, 2005.
| References |
|---|
|
|
|---|
2. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000; 20: 12621275.
3. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994; 94: 24932503.[Medline] [Order article via Infotrieve]
4. Guo H, Zucker S, Gordon MK, Toole BP, Biswas C. Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J Biol Chem. 1997; 272: 2427.
5. Major TC, Liang L, Lu X, Rosebury W, Bocan TM. Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma. Arterioscler Thromb Vasc Biol. 2002; 22: 12001207.
6. Verhoeven BAN, Hellings WE, Moll FL, de Vries JPPM, de Kleijn DPV, de Bruin P, Busser E, Schoneveld AH, Pasterkamp G. Carotid atherosclerotic plaques in patients with TIA and Stroke have unstable characteristics compared to plaques in asymptomatic and amaurosis fugax patients. J Vasc Surg. In press.
7. Pasterkamp G, Schoneveld AH, Hijnen DJ, de Kleijn DP, Teepen H, van der Wal AC, Borst C. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis. 2000; 150: 245253.[CrossRef][Medline] [Order article via Infotrieve]
8. Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell PR, Thompson MM. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke. 2000; 31: 4047.
9. Molloy KJ, Thompson MM, Jones JL, Schwalbe EC, Bell PR, Naylor AR, Loftus IM. Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation. 2004; 110: 337343.
10. Pasterkamp G, Schoneveld AH, van der Wal AC, Haudenschild CC, Clarijs RJ, Becker AE, Hillen B, Borst C. Relation of arterial geometry to luminal narrowing and histologic markers for plaque vulnerability: the remodeling paradox. J Am Coll Cardiol. 1998; 32: 655662.
11. Kanekura T, Miyauchi T, Tashiro M, Muramatsu T. Basigin, a new member of the immunoglobulin superfamily: genes in different mammalian species, glycosylation changes in the molecule from adult organs and possible variation in the N-terminal sequences. Cell Struct Funct. 1991; 16: 2330.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
Nitric Oxide Induces the Progression of Abdominal Aortic Aneurysms through the Matrix Metalloproteinase Inducer EMMPRIN Am. J. Pathol., October 1, 2009; 175(4): 1421 - 1430. |
||||
![]() |
M. G. Ionita, A. Vink, I. E. Dijke, J. D. Laman, W. Peeters, P. H. van der Kraak, F. L. Moll, J.-P. P.M. de Vries, G. Pasterkamp, and D. P.V. de Kleijn High Levels of Myeloid-Related Protein 14 in Human Atherosclerotic Plaques Correlate With the Characteristics of Rupture-Prone Lesions Arterioscler Thromb Vasc Biol, August 1, 2009; 29(8): 1220 - 1227. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Goyette, W. X. Yan, E. Yamen, Y. M. Chung, S. Y. Lim, K. Hsu, F. Rahimi, N. Di Girolamo, C. Song, W. Jessup, et al. Pleiotropic Roles of S100A12 in Coronary Atherosclerotic Plaque Formation and Rupture J. Immunol., July 1, 2009; 183(1): 593 - 603. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. T.G. Bot, I. E. Hoefer, J. P.G. Sluijter, P. van Vliet, A. M. Smits, F. Lebrin, F. Moll, J.-P. de Vries, P. Doevendans, J. J. Piek, et al. Increased Expression of the Transforming Growth Factor-{beta} Signaling Pathway, Endoglin, and Early Growth Response-1 in Stable Plaques Stroke, February 1, 2009; 40(2): 439 - 447. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Newby Metalloproteinase Expression in Monocytes and Macrophages and its Relationship to Atherosclerotic Plaque Instability Arterioscler Thromb Vasc Biol, December 1, 2008; 28(12): 2108 - 2114. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Welsh, P.H. Whincup, O. Papacosta, S.G. Wannamethee, L. Lennon, A. Thomson, A. Rumley, and G.D.O. Lowe Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men QJM, October 1, 2008; 101(10): 785 - 791. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Spinale Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function Physiol Rev, October 1, 2007; 87(4): 1285 - 1342. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Rodriguez-Feo, W. E. Hellings, B. A.N. Verhoeven, F. L. Moll, D. P.V. de Kleijn, J. Prendergast, Y. Gao, Y. van der Graaf, G. Tellides, W. C. Sessa, et al. Low Levels of Nogo-B in Human Carotid Atherosclerotic Plaques Are Associated With an Atheromatous Phenotype, Restenosis, and Stenosis Severity Arterioscler Thromb Vasc Biol, June 1, 2007; 27(6): 1354 - 1360. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Cummins, N. von Offenberg Sweeney, M. T. Killeen, Y. A. Birney, E. M. Redmond, and P. A. Cahill Cyclic strain-mediated matrix metalloproteinase regulation within the vascular endothelium: a force to be reckoned with Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H28 - H42. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Waxman, F. Ishibashi, and J. E. Muller Detection and Treatment of Vulnerable Plaques and Vulnerable Patients: Novel Approaches to Prevention of Coronary Events Circulation, November 28, 2006; 114(22): 2390 - 2411. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |